{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.6","upperLimit":"11.3","value":"9.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"}],"units":"Participants"}],"description":"Duration of Response was defined as the duration of overall response measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started). Per planned analysis, ORR by ICR was assessed for the TNBC Target Population only.","dispersionType":"95% Confidence Interval","groups":[{"description":"Overall 144 participants with TNBC were enrolled in the study and received at least one dose of SG. Of these 144 participants, 108 received at least 2 prior therapies for metastatic disease and were treated with SG at a starting dose of 10mg/kg. These 108 participants were included in the analysis of safety and were referred to as the TNBC Target Population.","id":"OG000","title":"TNBC Target Population"}],"paramType":"MEDIAN","populationDescription":"Target mTNBC: Participants with mTNBC who received at least 2 prior therapies for metastatic disease and who received SG at a dose of 10 mg/kg. Per planned analysis, ORR by ICR was assessed for the TNBC Target Population only.","reportingStatus":"POSTED","timeFrame":"Up to data cutoff date of 01 March 2019 (maximum duration: 74 months)","title":"Duration of Response by ICR","type":"SECONDARY","unitOfMeasure":"months"}